Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Amgen
(NASDAQ:AMGN)
Intraday
$267.60
-5.41
[-1.98%]
After-Hours
$267.60
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$267.60
-5.41
[-1.98%]
At close: Apr 25
$267.60
0
[0.00%]
After Hours: 7:36PM EDT
Get Report
Watch
Q1 2024 Earnings in 6 days from now on Thu May 2nd, after the market close
Conference call scheduled in 6 days at 16:30 PM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Amgen Stock (NASDAQ:AMGN)
Amgen Stock (NASDAQ: AMGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 24, 2024
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Vandana Singh
-
1 day ago
Friday, April 19, 2024
How Is The Market Feeling About Amgen?
Benzinga Insights
-
6 days ago
Wednesday, April 17, 2024
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Vandana Singh
-
Apr 17, 2024, 2:39PM
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
-
Apr 17, 2024, 8:21AM
TD Cowen Maintains Buy on Amgen, Lowers Price Target to $360
Benzinga Newsdesk
-
Apr 17, 2024, 6:04AM
Tuesday, April 16, 2024
Amgen Provides Update Regarding Results Of Phase 2a COURSE Trial For TEZSPIRE; Says Planning Underway For Phase 3 Development Of Tezepelumab In Chronic Obstructive Pulmonary Disease
Benzinga Newsdesk
-
Apr 16, 2024, 5:30PM
Monday, April 15, 2024
Amgen, Shell And More On CNBC's 'Final Trades'
Avi Kapoor
-
Apr 15, 2024, 8:29AM
Friday, April 12, 2024
Looking At Amgen's Recent Unusual Options Activity
Benzinga Insights
-
Apr 12, 2024, 12:31PM
Truist Securities Reiterates Buy on Amgen, Maintains $320 Price Target
Benzinga Newsdesk
-
Apr 12, 2024, 12:00PM
Wednesday, April 03, 2024
7 Analysts Have This To Say About Amgen
Benzinga Insights
-
Apr 3, 2024, 11:00AM
RBC Capital Reiterates Outperform on Amgen, Maintains $329 Price Target
Benzinga Newsdesk
-
Apr 3, 2024, 8:46AM
Tuesday, April 02, 2024
Amgen Unusual Options Activity For April 02
Benzinga Insights
-
Apr 2, 2024, 2:15PM
Monday, April 01, 2024
Redditors Identify 'Best Undervalued Stocks' For 2024
Surbhi Jain
-
Apr 1, 2024, 3:53PM
Thursday, March 28, 2024
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says
Vandana Singh
-
Mar 28, 2024, 2:28PM
Amgen Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
-
Mar 28, 2024, 12:03PM
Monday, March 18, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Mar 18, 2024, 1:35PM
Thursday, March 14, 2024
Looking At Amgen's Recent Unusual Options Activity
Benzinga Insights
-
Mar 14, 2024, 4:30PM
Wednesday, March 13, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
-
Mar 13, 2024, 8:24AM
Monday, March 11, 2024
Saturday, Amgen Announced New, 52-week Results From The Phase 3 Sprout Study Of Otezla (Apremilast) In Children And Adolescents Aged 6 To 17 Years With Moderate To Severe Plaque Psoriasis
Benzinga Newsdesk
-
Mar 11, 2024, 5:13AM
Friday, March 08, 2024
9 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Mar 8, 2024, 12:35PM
Thursday, March 07, 2024
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Vandana Singh
-
Mar 7, 2024, 9:15AM
Wednesday, March 06, 2024
(AMGN) - Analyzing Amgen's Short Interest
Benzinga Insights
-
Mar 6, 2024, 11:30AM
Friday, March 01, 2024
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
Chris Katje
-
Mar 1, 2024, 10:39AM
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
-
Mar 1, 2024, 7:52AM
Monday, February 26, 2024
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Vandana Singh
-
Feb 26, 2024, 1:25PM
Amgen Opens Biomanufacturing Site In Central Ohio
Benzinga Newsdesk
-
Feb 26, 2024, 9:03AM
Friday, February 23, 2024
Amgen Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
-
Feb 23, 2024, 1:01PM
Tuesday, February 20, 2024
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
Zacks
-
Feb 20, 2024, 12:56PM
Thursday, February 15, 2024
This Is What Whales Are Betting On Amgen
Benzinga Insights
-
Feb 15, 2024, 1:00PM
Monday, February 12, 2024
Behind the Scenes of Amgen's Latest Options Trends
Benzinga Insights
-
Feb 12, 2024, 11:00AM
Thursday, February 08, 2024
Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $350
Benzinga Newsdesk
-
Feb 8, 2024, 10:33AM
Wednesday, February 07, 2024
Investors' Focus Around Amgen's Obesity Drug Data Shadows Better Than Expected Q4 Earnings
Vandana Singh
-
Feb 7, 2024, 2:36PM
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
Piero Cingari
-
Feb 7, 2024, 1:40PM
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $329
Benzinga Newsdesk
-
Feb 7, 2024, 11:50AM
Amgen shares are trading lower after the company reported Q4 financial results.
Benzinga Newsdesk
-
Feb 7, 2024, 10:29AM
Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $350
Benzinga Newsdesk
-
Feb 7, 2024, 8:29AM
Tuesday, February 06, 2024
Amgen Sees FY24 Revenue $32.4B-$33.8B Vs $32.66B Est.; EPS $18.90-$20.30 Vs $20.00 Est.
Benzinga Newsdesk
-
Feb 6, 2024, 4:04PM
Amgen Q4 EPS $4.71 Beats $4.62 Estimate, Sales $8.20B Beat $8.13B Estimate
Benzinga Newsdesk
-
Feb 6, 2024, 4:01PM
Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?
Piero Cingari
-
Feb 6, 2024, 2:24PM
US Stocks Brace For Another Day In The Red As Rally Loses Steam: Analyst Sees Market Pullback On This Indicator
Shanthi Rexaline
-
Feb 6, 2024, 7:37AM
Earnings Scheduled For February 6, 2024
Benzinga Insights
-
Feb 6, 2024, 5:42AM
Monday, February 05, 2024
Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data
Vandana Singh
-
Feb 5, 2024, 10:05AM
Preview: Amgen's Earnings
Benzinga Insights
-
Feb 5, 2024, 9:00AM
Thursday, February 01, 2024
Oppenheimer Reiterates Outperform on Amgen, Maintains $350 Price Target
Benzinga Newsdesk
-
Feb 1, 2024, 12:29PM
Tuesday, January 30, 2024
Amgen Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
-
Jan 30, 2024, 3:00PM
Monday, January 29, 2024
Expert Outlook: Amgen Through The Eyes Of 11 Analysts
Benzinga Insights
-
Jan 29, 2024, 12:00PM
UBS Maintains Neutral on Amgen, Lowers Price Target to $314
Benzinga Newsdesk
-
Jan 29, 2024, 11:44AM
Friday, January 26, 2024
P/E Ratio Insights for Amgen
Benzinga Insights
-
Jan 26, 2024, 3:45PM
Wednesday, January 24, 2024
What's Going On Johnson & Johnson Stock Today?
Vandana Singh
-
Jan 24, 2024, 7:54AM
Amgen Has Completed 4,500 Square Foot Expansion, Capping Off A $27M Investment In Its Canadian Research Laboratory In Burnaby
Benzinga Newsdesk
-
Jan 24, 2024, 7:18AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch